A preclinical humanized chimeric model to investigate novel therapeutic strategies against breast cancer bone metastasis

临床前人源化嵌合模型研究乳腺癌骨转移的新治疗策略

• 批准号: nhmrc : GNT1082313
• 负责人: Dr Brett Hollier
• 金额: $ 67.45万
• 依托单位: Queensland University of Technology
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/preclinical-humanized-chimeric-bone-metastasis/1345453
• 关键词: preclinical; humanized; chimeric; model; investigate

Using the humanized in-vivo model presented, researchers are in a unique position to develop and evaluate novel therapeutic strategies against breast cancer bone metastasis at multiple intervention points from the primary tumour to bone metastasis. This model makes it possible to study anti-cancer and anti-resorptive effects of human-specific drugs such as the monoclonal antibody Denosumab. The model eventually may help to decrease morbidity and mortality of breast cancer patients.

利用所提出的人源化体内模型，研究人员在从原发肿瘤到骨转移的多个干预点上开发和评估新的乳腺癌骨转移治疗策略具有独特的地位。该模型使研究人类特异性药物（如单克隆抗体Denosumab）的抗癌和抗吸收作用成为可能。该模型最终可能有助于降低乳腺癌患者的发病率和死亡率。